Eli Lilly announced on Tuesday that it will invest $5 billion to build a new manufacturing facility in Goochland County, Virginia, aimed at boosting production of advanced cancer treatments and other innovative medicines. This project marks the first of four new U.S. facilities the company has committed to as part of its $27 billion domestic expansion plan, adding to $23 billion already invested since 2020. The drugmaker expects all four plants to be operational within five years, with the remaining sites to be revealed later this year.
The Virginia facility will focus on producing active ingredients for cancer and autoimmune treatments, particularly antibody drug conjugates. These specialized therapies combine monoclonal antibodies with targeted payloads designed to attack cancer cells while sparing healthy tissue. Eli Lilly emphasized that the plant will be its first dedicated site for both active ingredients and finished products within its bioconjugate platform, a key growth area for the company.
According to the company, the new plant will not only expand capacity for cutting-edge biologics but also reduce reliance on third-party manufacturers and European sites, consolidating more of its production in the U.S. Leadership highlighted the state’s strong logistics, skilled workforce, and existing infrastructure as major factors behind the decision. Construction has already begun, repurposing a site originally intended for another industrial use.
The Virginia project will bring more than 650 permanent jobs, including engineers, scientists, operations staff, and lab technicians, along with 1,800 construction jobs during development. Advanced technologies such as machine learning and artificial intelligence will be integrated into operations to improve efficiency, safety, and reliability in the production process.
While Eli Lilly’s strong presence in the fast-growing weight loss and diabetes drug markets has driven much of its recent growth, the new facility underscores the company’s long-term strategy. Beyond its blockbuster products Zepbound and Mounjaro, the company is investing heavily in a pipeline targeting cancer, Alzheimer’s disease, autoimmune conditions, and other serious illnesses. By diversifying its portfolio and expanding U.S. capacity, Eli Lilly aims to strengthen its position in the pharmaceutical industry for decades to come.
The Virginia plant is part of a broader industry shift toward expanding domestic manufacturing. Recent tax reforms have also made U.S. investment more attractive for companies like Eli Lilly, which sees strong incentives to build new capacity closer to home while advancing therapies that address some of the world’s most challenging health conditions.
READ MORE: